ATAI Life Sciences NV banner

ATAI Life Sciences NV
NASDAQ:ATAI

Watchlist Manager
ATAI Life Sciences NV Logo
ATAI Life Sciences NV
NASDAQ:ATAI
Watchlist
Price: 3.79 USD -1.56%
Market Cap: $1.4B

Multiples-Based Value

The Multiples-Based Value for ATAI Life Sciences NV (ATAI) under the Base Case is hidden USD. Compared with the current market price of 3.79 USD, the stock appears hidden .

Multiples-Based Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

ATAI Multiples-Based Value
LOCKED
Unlock
Worst Case
Base Case
Best Case

Multiples Across Competitors

ATAI Competitors Multiples
ATAI Life Sciences NV Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
DE
ATAI Life Sciences NV
NASDAQ:ATAI
1.4B USD 336.7 -2.1 -10.2 -10.1
US
Eli Lilly and Co
NYSE:LLY
879.7B USD 13.8 43.7 29.5 31.5
US
Johnson & Johnson
NYSE:JNJ
574.1B USD 6.1 21.6 15 18.4
UK
AstraZeneca PLC
LSE:AZN
236B GBP 5.3 30.6 16.9 23.8
CH
Roche Holding AG
SIX:ROG
248.4B CHF 4 19.2 11.4 12.8
US
Merck & Co Inc
NYSE:MRK
295.2B USD 4.7 16.7 10.3 12.6
CH
Novartis AG
SIX:NOVN
229.9B CHF 5.2 20.8 12.9 16.6
IE
Endo International PLC
LSE:0Y5F
244.4B USD 105.4 -83.6 386.8 970
DK
Novo Nordisk A/S
CSE:NOVO B
1T DKK 3.5 10.5 7.8 9.1
US
Pfizer Inc
NYSE:PFE
154.1B USD 2.5 19.9 7.7 10.2
US
Bristol-Myers Squibb Co
NYSE:BMY
116.1B USD 2.4 16.7 7.1 8.7
P/E Multiple
Earnings Growth PEG
DE
ATAI Life Sciences NV
NASDAQ:ATAI
Average P/E: 22.2
Negative Multiple: -2.1
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
43.7
32%
1.4
US
Johnson & Johnson
NYSE:JNJ
21.6
7%
3.1
UK
AstraZeneca PLC
LSE:AZN
30.6
26%
1.2
CH
Roche Holding AG
SIX:ROG
19.2
14%
1.4
US
Merck & Co Inc
NYSE:MRK
16.7
14%
1.2
CH
Novartis AG
SIX:NOVN
20.8
14%
1.5
IE
E
Endo International PLC
LSE:0Y5F
Negative Multiple: -83.6 N/A N/A
DK
Novo Nordisk A/S
CSE:NOVO B
10.5
1%
10.5
US
Pfizer Inc
NYSE:PFE
19.9
22%
0.9
US
Bristol-Myers Squibb Co
NYSE:BMY
16.7
16%
1
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
DE
ATAI Life Sciences NV
NASDAQ:ATAI
Average EV/EBITDA: 50.5
Negative Multiple: -10.2
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
29.5
22%
1.3
US
Johnson & Johnson
NYSE:JNJ
15
2%
7.5
UK
AstraZeneca PLC
LSE:AZN
16.9
13%
1.3
CH
Roche Holding AG
SIX:ROG
11.4
6%
1.9
US
Merck & Co Inc
NYSE:MRK
10.3
3%
3.4
CH
Novartis AG
SIX:NOVN
12.9
5%
2.6
IE
E
Endo International PLC
LSE:0Y5F
386.8
N/A N/A
DK
Novo Nordisk A/S
CSE:NOVO B
7.8
1%
7.8
US
Pfizer Inc
NYSE:PFE
7.7
-9%
N/A
US
Bristol-Myers Squibb Co
NYSE:BMY
7.1
-10%
N/A
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
DE
ATAI Life Sciences NV
NASDAQ:ATAI
Average EV/EBIT: 111.4
Negative Multiple: -10.1
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
31.5
22%
1.4
US
Johnson & Johnson
NYSE:JNJ
18.4
6%
3.1
UK
AstraZeneca PLC
LSE:AZN
23.8
21%
1.1
CH
Roche Holding AG
SIX:ROG
12.8
6%
2.1
US
Merck & Co Inc
NYSE:MRK
12.6
6%
2.1
CH
Novartis AG
SIX:NOVN
16.6
9%
1.8
IE
E
Endo International PLC
LSE:0Y5F
970
N/A N/A
DK
Novo Nordisk A/S
CSE:NOVO B
9.1
2%
4.6
US
Pfizer Inc
NYSE:PFE
10.2
-4%
N/A
US
Bristol-Myers Squibb Co
NYSE:BMY
8.7
-7%
N/A
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett